Association between shoulder joint radiation dose and arm morbidity in the randomized breast cancer trial SENOMAC
(2026) In Radiotherapy and Oncology 218.- Abstract
Background: Postoperative lymph node irradiation can affect shoulder morbidity in breast cancer patients, yet widely accepted dose-volume constraints for the shoulder joint are lacking. The SENOMAC trial randomized patients with breast cancer and 1–2 sentinel lymph node (SLN) macrometastases to axillary lymph node dissection (ALND) or SLN biopsy only. We aimed to analyze the association between the radiation dose to the shoulder joint and patient-reported arm morbidity one and three years after surgery using SENOMAC data. Methods: Radiotherapy plans from 868 Swedish SENOMAC patients randomized 2015–2019 were collected. The humeral head was auto-segmented, and a 1 cm margin added to represent the shoulder joint. Arm morbidity was... (More)
Background: Postoperative lymph node irradiation can affect shoulder morbidity in breast cancer patients, yet widely accepted dose-volume constraints for the shoulder joint are lacking. The SENOMAC trial randomized patients with breast cancer and 1–2 sentinel lymph node (SLN) macrometastases to axillary lymph node dissection (ALND) or SLN biopsy only. We aimed to analyze the association between the radiation dose to the shoulder joint and patient-reported arm morbidity one and three years after surgery using SENOMAC data. Methods: Radiotherapy plans from 868 Swedish SENOMAC patients randomized 2015–2019 were collected. The humeral head was auto-segmented, and a 1 cm margin added to represent the shoulder joint. Arm morbidity was assessed using the Lymph-ICF questionnaire, focusing on questions regarding physical arm function and shoulder-related mobility tasks. Results: The radiation dose was evaluable for 386 patients receiving ALND and 421 receiving SLN biopsy. The dose distribution to the shoulder joint was similar in both study groups. In the SLN group, a higher near-maximum dose (D0.5cc) was associated with significantly worse arm morbidity scores three years after surgery, particularly among patients treated with breast-conserving surgery. No association was found in the ALND group. No dose thresholds for development of arm/shoulder related side effects could be identified. Conclusion: Our results indicate a possible association between maximum radiation dose to the shoulder joint and subsequent side effects. Extended follow-up within SENOMAC will provide further insights into the incidence of arm morbidity in relation to radiotherapy dose over time.
(Less)
- author
- organization
-
- Breast cancer treatment
- LUCC: Lund University Cancer Centre
- Department of Clinical Sciences, Lund
- Medical Radiation Physics, Malmö (research group)
- Radiotherapy Physics (research group)
- Medical Radiation Physics, Lund
- The Liquid Biopsy and Tumor Progression in Breast Cancer (research group)
- Breast Cancer Surgery (research group)
- Surgery (Lund)
- publishing date
- 2026
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Breast cancer, Dose–volume constraints, Nodal radiotherapy, Patient-reported arm morbidity, SENOMAC trial, Shoulder joint
- in
- Radiotherapy and Oncology
- volume
- 218
- article number
- 111454
- publisher
- Elsevier
- external identifiers
-
- pmid:41730479
- scopus:105030663548
- ISSN
- 0167-8140
- DOI
- 10.1016/j.radonc.2026.111454
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2026 The Author(s)
- id
- 970775f0-857f-49a8-b045-070ebf175252
- date added to LUP
- 2026-04-21 16:26:12
- date last changed
- 2026-05-19 18:12:57
@article{970775f0-857f-49a8-b045-070ebf175252,
abstract = {{<p>Background: Postoperative lymph node irradiation can affect shoulder morbidity in breast cancer patients, yet widely accepted dose-volume constraints for the shoulder joint are lacking. The SENOMAC trial randomized patients with breast cancer and 1–2 sentinel lymph node (SLN) macrometastases to axillary lymph node dissection (ALND) or SLN biopsy only. We aimed to analyze the association between the radiation dose to the shoulder joint and patient-reported arm morbidity one and three years after surgery using SENOMAC data. Methods: Radiotherapy plans from 868 Swedish SENOMAC patients randomized 2015–2019 were collected. The humeral head was auto-segmented, and a 1 cm margin added to represent the shoulder joint. Arm morbidity was assessed using the Lymph-ICF questionnaire, focusing on questions regarding physical arm function and shoulder-related mobility tasks. Results: The radiation dose was evaluable for 386 patients receiving ALND and 421 receiving SLN biopsy. The dose distribution to the shoulder joint was similar in both study groups. In the SLN group, a higher near-maximum dose (D<sub>0.5cc</sub>) was associated with significantly worse arm morbidity scores three years after surgery, particularly among patients treated with breast-conserving surgery. No association was found in the ALND group. No dose thresholds for development of arm/shoulder related side effects could be identified. Conclusion: Our results indicate a possible association between maximum radiation dose to the shoulder joint and subsequent side effects. Extended follow-up within SENOMAC will provide further insights into the incidence of arm morbidity in relation to radiotherapy dose over time.</p>}},
author = {{Alkner, Sara and Appelgren, Matilda and Szulkin, Robert and Wieslander, Elinore and Rogowski, Viktor and Gustafsson, Christian Jamtheim and Nissen, Henrik Dahl and Sackey, Helena and Lundstedt, Dan and Andersson, Yvette and Bergkvist, Leif and Frisell, Jan and Olofsson Bagge, Roger and Sund, Malin and Rydén, Lisa and Offersen, Birgitte Vrou and de Boniface, Jana}},
issn = {{0167-8140}},
keywords = {{Breast cancer; Dose–volume constraints; Nodal radiotherapy; Patient-reported arm morbidity; SENOMAC trial; Shoulder joint}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{Radiotherapy and Oncology}},
title = {{Association between shoulder joint radiation dose and arm morbidity in the randomized breast cancer trial SENOMAC}},
url = {{http://dx.doi.org/10.1016/j.radonc.2026.111454}},
doi = {{10.1016/j.radonc.2026.111454}},
volume = {{218}},
year = {{2026}},
}
